Mereo Biopharma Group Plc ADR (NASDAQ: MREO) has seen a rise in its stock price by 3.10 in relation to its previous close of 2.58. However, the company has experienced a -2.92% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-12 that The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is It Worth Investing in Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Right Now?
Additionally, the 36-month beta value for MREO is 0.85. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MREO is 140.06M and currently, short sellers hold a 1.66% ratio of that float. The average trading volume of MREO on April 18, 2024 was 1.65M shares.
MREO’s Market Performance
The stock of Mereo Biopharma Group Plc ADR (MREO) has seen a -2.92% decrease in the past week, with a -12.50% drop in the past month, and a -10.44% fall in the past quarter. The volatility ratio for the week is 5.98%, and the volatility levels for the past 30 days are at 6.15% for MREO. The simple moving average for the last 20 days is -12.28% for MREO stock, with a simple moving average of 18.24% for the last 200 days.
Analysts’ Opinion of MREO
Many brokerage firms have already submitted their reports for MREO stocks, with BTIG Research repeating the rating for MREO by listing it as a “Buy.” The predicted price for MREO in the upcoming period, according to BTIG Research is $4 based on the research report published on October 13, 2023 of the previous year 2023.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see MREO reach a price target of $4. The rating they have provided for MREO stocks is “Overweight” according to the report published on August 12th, 2022.
BTIG Research gave a rating of “Buy” to MREO, setting the target price at $10 in the report published on May 05th of the previous year.
MREO Trading at -21.59% from the 50-Day Moving Average
After a stumble in the market that brought MREO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.99% of loss for the given period.
Volatility was left at 6.15%, however, over the last 30 days, the volatility rate increased by 5.98%, as shares sank -14.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.82% lower at present.
During the last 5 trading sessions, MREO fell by -3.14%, which changed the moving average for the period of 200-days by +105.74% in comparison to the 20-day moving average, which settled at $3.01. In addition, Mereo Biopharma Group Plc ADR saw 15.15% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MREO
Current profitability levels for the company are sitting at:
- -4.7 for the present operating margin
- 0.64 for the gross margin
The net margin for Mereo Biopharma Group Plc ADR stands at -3.56. The total capital return value is set at -0.72. Equity return is now at value -39.59, with -26.75 for asset returns.
Based on Mereo Biopharma Group Plc ADR (MREO), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -6.27. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -14.83.
Currently, EBITDA for the company is -23.95 million with net debt to EBITDA at 1.27. When we switch over and look at the enterprise to sales, we see a ratio of 36.37. The receivables turnover for the company is 2.36for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.11.
Conclusion
In conclusion, Mereo Biopharma Group Plc ADR (MREO) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
